1-3 of 3
Michael Hedenus, MD, PhD
Close
Sort by
Journal Articles

Intravenous Ferric Carboxymaltose As Sole Anemia Therapy In Patients With Lymphoid Malignancies, Chemotherapy-Induced Anemia and Functional Iron Deficiency

Michael Hedenus, MD, PhD, Torbjorn Karlsson, MD, PhD, Heinz Ludwig, MD, Marcel Felder, MD, Bernard Roubert, MSc, Gunnar Birgegard, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 3439.
https://doi.org/10.1182/blood.V122.21.3439.3439
Published: 2013
Journal Articles

Rituximab Maintenance Significantly Prolongs Event Free (EFS) and Progression Free Survival (PFS) In Male Patients With Aggressive B-Cell Lymphoma In The NHL13 Study

Ulrich Jaeger, Marek Trneny, MD, Ph.D., Helen Melzer, Michael Praxmarer, Michael A. Fridrik, MD, Weerasak Nawarawong, MD, Dina Ben Yehuda, Biljana Mihaljevic, PhD, Osman Ilhan, MD, Prof, Veronika Ballova, MD, Michael Hedenus, MD, PhD, Liang-Tsai Hsiao, MD, Wing-Yan Au, MD, Josef Thaler, MD, Gerhard Weidinger, MD, Felix Keil, MD, Christian Dittrich, Cathrin Skrabs, Daniela Wolkersdorfer, Anton Klingler, Richard Greil, MD, David Goldstein
Journal: Blood
Blood (2013) 122 (21): 851.
https://doi.org/10.1182/blood.V122.21.851.851
Published: 2013
Journal Articles

Epoetin Beta with Intravenous Iron Results in Overall Cost Savings in a Population of Anemic Patients with Lymphoid Malignancies Not Receiving Chemotherapy.

Michael Hedenus, MD, PhD, Per Näsman, PhL
Journal: Blood
Blood (2007) 110 (11): 5179.
https://doi.org/10.1182/blood.V110.11.5179.5179
Published: 2007